{
    "clinical_study": {
        "@rank": "83883", 
        "brief_summary": {
            "textblock": "Assess efficacy of piperacillin/tazobactam in reducing the cases of colonization and\n      infection of bacteria."
        }, 
        "brief_title": "Study Evaluating the Association of Antibiotic Measures and Control of Bacterial Resistance", 
        "completion_date": {
            "#text": "February 2007", 
            "@type": "Actual"
        }, 
        "condition": "Bacterial Infections", 
        "condition_browse": {
            "mesh_term": "Bacterial Infections"
        }, 
        "detailed_description": {
            "textblock": "Primarily, this study is designed to assess the efficacy of piperacillin/tazobactam in\n      reducing the cases of colonization and infection of extended-spectrum betalactamases (ESBLs)\n      producing E.coli or K pneumoniae, S aureus methicillin resistant (MRSA) and Enterococcus\n      vancomycin resistant (VRE). Secondly, this study plans to determine the acquisition rate of\n      ESBL producing E Coli or K pneumoniae, methicillin resistant S Aureus (MRSA) and vancomycin\n      resistant Enterococcus spp (VRE), both pre- and post-intervention."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "All patients admitted in ICU will be enrolled (who qualify for treatment)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Intensive Care Unit (ICU)"
            }
        }, 
        "enrollment": {
            "#text": "335", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 6, 2009", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01788449", 
            "org_study_id": "0910X-101852"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Anti-Bacterial Agents", 
                "Antibiotics, Antitubercular"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Antibiotic Bacterial Resistance", 
        "lastchanged_date": "February 12, 2013", 
        "number_of_groups": "1", 
        "official_title": "Association of Antibiotic Measures and Control of Bacterial Resistance", 
        "overall_official": {
            "affiliation": "Wyeth is now a wholly owned subsidiary of Pfizer", 
            "last_name": "Medical Monitor", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Spain: Ministry of Health", 
                "Spain: Ministry of Health and Consumption", 
                "Spain: Spanish Agency of Medicines"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2007", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Endpoints will be efficacy of piperacillin/tazobactam in reducing colonization rates and infection of E coli or K pneumoniae, vancomycin resistant enterococcus and methicillin resistant S aureus", 
            "safety_issue": "No", 
            "time_frame": "8 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01788449"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Endpoints will be acquisition and infection rate of ESBL producing E coli or K pneumoniae, vancomycin resistant enterococcus and methicillin resistant S aureus", 
            "safety_issue": "No", 
            "time_frame": "8 months"
        }, 
        "source": "Wyeth is now a wholly owned subsidiary of Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Wyeth is now a wholly owned subsidiary of Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2005", 
        "study_design": "Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "February 2013"
    }
}